期刊文献+

塞来考昔对女性卵巢功能的影响 预览 被引量:1

Influence of celecoxib on ovary function
在线阅读 下载PDF
收藏 分享 导出
摘要 目的:观察塞来考昔(celecoxib)对女性卵巢功能的影响.方法:56例痛经病人分为2组,A组给予塞来考昔治疗1 wk,B组给予山莨菪碱治疗1 wk,采用对照的方法进行临床试验.结果:塞来考昔对治疗前后病人性激素(PRL,E2,LH,FSH)水平无明显影响(P>0.05),与山莨菪碱治疗组比较无显著差异(P>0.05),其对滤泡直径的影响与山莨菪碱治疗组比较亦无显著差异[(20.1±s 1.3)mm vs(19.4±1.1)mm, P>0.05].结论:短期使用塞来考昔对女性卵巢功能可能无明显影响. AIM: To investigate the influence of celecoxib therapy on ovary function. METHODS: Fifty-six women with menstrual pain were divided into two groups (group A and group B),with group A treated with celecoxib and group B with anisodamine for 1 wk,sex hormone concentrations and the diameter of ovary follicle were compared. RESULTS: Sex hormone concentrations (PRL,E_2,LH and FSH)do not be affected before and after treatment with celecoxib ( P >0.05)and have no significant difference compared with anisodamine treating. The diameter of ovary follicle in group A do not be changed compared with group B( P >0.05). CONCLUSION: Short-term using of celecoxib do not affects ovary function.
作者 毕会民 胡胜 甘佩珍 BI Hui-min,HU Sheng,GAN Pei-zhen (Department of endocrinology,Renmin hospital of Wuhan University, Wuhan HUBEI 430060, China)
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2004年第8期 538-539,共2页 Chinese Journal of New Drugs and Clinical Remedies
关键词 卵巢功能试验 消炎药 非甾类 药物疗法 塞来考昔 ovarian function tests anti-inflammatory agents,non-steroidal drug therapy celecoxib
  • 相关文献

参考文献8

  • 1[1]FITZGERALD GA, PATRONO C. The Coxibs, selective inhibitors of cyclooxygenase 2[J]. N Engl J Med , 2001, 345(6):433-442. 被引量:1
  • 2程虹,肖从新,马汉林.塞来考昔和布洛芬治疗骨关节炎的比较[J].中国新药与临床杂志,2002,21(11):652-653. 被引量:3
  • 3[3]LIM H, PARIA BC, DAS SK, et al. Multiple female reproductive failures in cyclooxygenase 2-deficient mice[J]. Cell, 1997,91(2): 197-208. 被引量:1
  • 4[4]NORMAN RJ. Reproductive consequences of Cox-2 inhibition[J]. Lancet,2001,358(9290):1287-1288. 被引量:1
  • 5[5]PALL ME, FRIDEN BE, BRANNSTROM M. Induction of follicular rupture in the human by the selective Cox-2 inhibitor Rofecoxib: a randomised double-blind study[J]. Hum Reprod, 2001,16(7):1323-1328. 被引量:1
  • 6[6]See above 被引量:1
  • 7[7]CHENG H, XIAO CX, MA HL. Celecoxib vs ibuprofen in treating osteoarthritis[J]. Chin J New Drugs Clin Rem (in Chinese), 2002, 21(11): 652-654. 被引量:1
  • 8[8]-[5] See above 被引量:1

二级参考文献2

共引文献2

同被引文献16

  • 1Zhao SZ, Mcmillen JI, Markenson JA, et al. Evaluation of the functional status aspects of Health-Related Quality of Life of patients with osteoarthritis treated with Celecoxib. Pharmacotherapy, 1999, 19(11): 1269-1278. 被引量:1
  • 2Zhao SZ, FiechtnerJJ, Tindall EA, et al. Evaluation of Health- Related Quality of Life of rheumatoid arthritis patients treated with Celecoxib. Arthritis Care and Research, 2000, 13(2): 112-121. 被引量:1
  • 3Becker MC, Wang TH, Wisniewski L, et al. Rationale, design, and governance of prospective randomized evaluation of Celecoxib inte- grated safety versus Ibuprofen or Naproxen (PRECISION), a cardio- vascular end point trial of nonsteroidal anti-inflammatory agents in patients with arthritis. Am Heart J, 2009, 157(4): 606-612. 被引量:1
  • 4Solomon SD, Wittes J, Finn PV, et al. Cardiovascular risk of Celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulatio, 2008, 117(16): 2104-2113. 被引量:1
  • 5Lelorier J, Fitzsimon C, Keresteci M, et al. Drug utilization review of Celecoxib in Ontario. Rheumatology, 2003, 42(suppl 3): 11-16. 被引量:1
  • 6Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics, 2004, 22(2 Suppl 1): 1-12. 被引量:1
  • 7Nivsrkar M. Improvement in circulating superoxide dismutase levels: Role of nonsteroidal anti-inflammatory drugs in rheumatoid arthritis biochemical and biophysical. Research Communications, 2000, 270(3): 714-716. 被引量:1
  • 8Niederberger E, Manderscheid C, Gr6sch S, et al. Effects of the se- lective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells. Biochem Pharmacol, 2004, 68(2): 341-350. 被引量:1
  • 9Laine L, Connor LG, Reicin A, et al. Serious lower gastrointestinal clinical events with nonselective NSAID or Coxib Use. Gastroenterology, 2003, 124(2): 288-292. 被引量:1
  • 10Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials, 1996, 17(1): 1-12. 被引量:1

引证文献1

二级引证文献38

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈